Angina Pectoris

Categories: Blood diseases, Cardiovascular diseases, Oral diseases, Rare diseases

Aliases & Classifications for Angina Pectoris

MalaCards integrated aliases for Angina Pectoris:

Name: Angina Pectoris 40 36 37 17 32
Prinzmetal's Variant Angina 12 74 52 71
Prinzmetal Angina 12 52 15
Variant Angina 12 52 54
Coronary Artery Vasospasm 52 71
Angina Pectoris, Variant 43 71
Prinzmetal's Angina 12 17
Angina Inversa 12 52
Angina 42 62
Variant Angina Pectoris 12
Vasospastic Angina 52


External Ids:

Disease Ontology 12 DOID:0111151
KEGG 36 H01632
MeSH 43 D000788
ICD10 32 I20 I20.1 I20.9
UMLS 71 C0002963 C0010073 C2931193

Summaries for Angina Pectoris

NIH Rare Diseases : 52 Prinzmetal's variant angina (PVA) is characterized by recurrent episodes of chest pain (angina ) that usually occur when a person is at rest, between midnight and early morning. "Typical" angina, by contrast, is often triggered by physical exertion or emotional stress. Episodes of PVA can be very painful, and may last from several minutes to thirty minutes. In some cases the pain may spread from the chest to the head, shoulder, or arm. The pain associated with PVA is caused by a spasm in the arteries that supply blood to the heart muscle (coronary arteries ). This results in an obstruction of blood flow. In some people, persistent spasms increase the risk for serious complications such as a life-threatening arrhythmia or heart attack . PVA most commonly occurs in people who smoke and people who have high cholesterol or high blood pressure . In many cases it occurs for unknown reasons in otherwise healthy people. In some cases it may be triggered by alcohol withdrawal, stress, exposure to cold, certain medications, or use of stimulants such as cocaine. The diagnosis of PVA involves findings on an electrocardiogram , evidence of the spasms on angiogram , and relief of sudden symptoms with medicines called nitrates . Treatment during an episode to relieve pain and shorten its duration involves sublingual nitroglycerin (a nitrate). Treatment to reduce the frequency of episodes and possibly reduce the risk of serious complications involves calcium channel blockers or long-acting nitrates . For people with PVA who smoke, quitting smoking can lead to a significant decrease in the frequency of episodes. While most people with PVA do not experience serious complications, it is a chronic condition that needs to be monitored over time.

MalaCards based summary : Angina Pectoris, also known as prinzmetal's variant angina, is related to intermittent claudication and coronary thrombosis, and has symptoms including other and unspecified angina pectoris An important gene associated with Angina Pectoris is EDN1 (Endothelin 1), and among its related pathways/superpathways are cAMP signaling pathway and Folate Metabolism. The drugs Glyburide and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 A coronary artery vasospasm characterized by spasms of the coronary arteries that occur while at rest, generally late at night or early in the morning, resulting in severe chest pain with preserved exercise capacity.

MedlinePlus : 42 Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back. Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina: Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help. Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute

KEGG : 36 Angina pectoris is defined as cardiac-induced pain arising from a lack of myocardial oxygen. "Angina" is used to describe clinical symptoms such as discomfort in the chest, jaw, shoulder, back, or arms that are induced by physical exertion or emotional stress and subside with rest or treatment with nitroglycerin. Angina is clinically classified into stable angina (SA) and unstable angina (UA). SA is a chronic medical condition while UA is an acute coronary syndrome. Among the causes of angina pectoris, the most common is coronary artery disease (CAD). At the cellular level, angina pectoris is a result of increased myocardial oxygen demand or decreased myocardial oxygen supply.

PubMed Health : 62 About angina: Angina (an-JI-nuh or AN-juh-nuh) is chest pain or discomfort that occurs if an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also can occur in your shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion. Angina isn't a disease; it's a symptom of an underlying heart problem. Angina usually is a symptom of coronary heart disease (CHD). CHD is the most common type of heart disease in adults. It occurs if a waxy substance called plaque (plak) builds up on the inner walls of your coronary arteries. These arteries carry oxygen-rich blood to your heart.

Wikipedia : 74 Variant angina, and less commonly Prinzmetal angina, vasospastic angina, angina inversa, coronary vessel... more...

Related Diseases for Angina Pectoris

Diseases related to Angina Pectoris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 898)
# Related Disease Score Top Affiliating Genes
1 intermittent claudication 31.5 IL6 CRP ACE
2 coronary thrombosis 31.3 PLAT F3 CRP ACE
3 syphilis 31.0 IL6 CRP ACE
4 raynaud disease 30.9 EDN1 CRP ACE
5 proteasome-associated autoinflammatory syndrome 1 30.8 IL6 CRP ADIPOQ
6 first-degree atrioventricular block 30.8 NPPB CRP ACE
7 aortic aneurysm, familial abdominal, 1 30.8 IL6 CRP ACE
8 aortic valve insufficiency 30.8 TNNI3 NPPB CRP ACE
9 mediastinitis 30.8 INS F3 CRP
10 cardiogenic shock 30.8 PLAT PIK3C2A NPPB CRP
11 mitral valve stenosis 30.8 NPPB F3 CRP ACE
12 thrombosis 30.7 PLAT NOS3 LPA F3
13 ileus 30.7 INS IL6 CRP
14 anterolateral myocardial infarction 30.6 PLAT NPPB ACE
15 atrioventricular block 30.6 TNNI3 PIK3C2A NPPB ACE
16 kawasaki disease 30.6 NPPB IL6 CRP
17 granulomatous angiitis 30.6 CRP ACE
18 takayasu arteritis 30.6 IL6 F3 EDN1 CRP
19 cardiac arrest 30.6 PIK3C2A NPPB KNG1 ACE
20 hemopericardium 30.6 TNNI3 F3
21 rheumatic fever 30.5 NPPB IL6 ACE
22 complex regional pain syndrome 30.4 IL6 EDN1 ACE
23 right bundle branch block 30.4 TNNI3 NPPB ACE
24 necrotizing fasciitis 30.4 PIK3C2A IL6 CRP
25 constrictive pericarditis 30.4 TNNI3 NPPB CRP ACE
26 thrombocytosis 30.4 IL6 F3 CRP
27 pain agnosia 30.4 KNG1 IL6 ADRB1
28 antiphospholipid syndrome 30.3 PLAT F3 CRP
29 sickle cell anemia 30.3 IL6 EDN1 CRP
30 thrombophlebitis 30.3 PLAT F3 CRP
31 toxic shock syndrome 30.3 IL6 F3 CRP
32 acute myocarditis 30.3 TNNI3 NPPB CRP ACE
33 exanthem 30.3 PIK3C2A IL6 F3 CRP ACE
34 cardiac rupture 30.2 PLAT CRP
35 eisenmenger syndrome 30.2 PLAT EDN1
36 left bundle branch hemiblock 30.2 TNNI3 PIK3C2A NPPB CRP ACE
37 heart valve disease 30.2 TNNI3 NPPB LPA CRP ACE
38 purpura 30.2 IL6 F3 CRP ACE
39 hypercholesterolemia, familial, 1 30.2 NOS3 LPA INS CRP APOA1 ACE
40 hyperglycemia 30.2 NOS3 INS IL6 ADIPOQ
41 cerebral atherosclerosis 30.1 LPA CRP APOA1 ACE
42 lemierre's syndrome 30.1 F3 CRP
43 mental depression 30.1 IL6 HTR1B CRP
44 atrial standstill 1 30.1 TNNI3 NPPB ADRB1 ACE
45 rheumatic heart disease 30.1 NPPB IL6 ACE
46 coronary stenosis 30.1 TNNI3 PIK3C2A NPPB IL6 CRP APOA1
47 intermediate coronary syndrome 30.1 TNNI3 PLAT PIK3C2A MB LPA INS
48 homocysteinemia 30.0 NOS3 LPA CRP
49 mitral valve insufficiency 30.0 TNNI3 PIK3C2A NPPB CRP ACE
50 retinal artery occlusion 30.0 IL6 CRP ACE

Comorbidity relations with Angina Pectoris via Phenotypic Disease Network (PDN):

Esophagitis Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease

Graphical network of the top 20 diseases related to Angina Pectoris:

Diseases related to Angina Pectoris

Symptoms & Phenotypes for Angina Pectoris

UMLS symptoms related to Angina Pectoris:

angina pectoris, other and unspecified angina pectoris

MGI Mouse Phenotypes related to Angina Pectoris:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 ACE ADIPOQ ADRB1 APOA1 CRP EDN1
2 growth/size/body region MP:0005378 10.18 ACE ADIPOQ ADRB1 EDN1 F3 HTR1B
3 homeostasis/metabolism MP:0005376 10.17 ACE ADIPOQ ADRB1 APOA1 CRP EDN1
4 endocrine/exocrine gland MP:0005379 10.1 ACE ADIPOQ ADRB1 APOA1 EDN1 HTR1B
5 mortality/aging MP:0010768 10.07 ACE ADIPOQ ADRB1 EDN1 F3 HTR1B
6 adipose tissue MP:0005375 10.06 ACE ADIPOQ ADRB1 HTR1B IL6 INS
7 muscle MP:0005369 9.9 ADIPOQ ADRB1 EDN1 F3 HTR1B IL6
8 renal/urinary system MP:0005367 9.5 ACE ADIPOQ EDN1 IL6 INS NOS3
9 respiratory system MP:0005388 9.17 ADIPOQ F3 IL6 MB NOS3 PLAT

Drugs & Therapeutics for Angina Pectoris

PubMed Health treatment related to Angina Pectoris: 62

Treatments for angina include lifestyle changes, medicines, medical procedures, cardiac rehabilitation (rehab), and other therapies . The main goals of treatment are to: Reduce pain and discomfort and how often it occurs Prevent or lower your risk for heart attack and death by treating your underlying heart condition Lifestyle changes and medicines may be the only treatments needed if your symptoms are mild and aren't getting worse. If lifestyle changes and medicines don't control angina , you may need medical procedures or cardiac rehab . Unstable angina is an emergency condition that requires treatment in a hospital.

Drugs for Angina Pectoris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 576)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Glyburide Approved Phase 4 10238-21-8 3488
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
Trimetazidine Approved, Investigational Phase 4 5011-34-7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
Thrombin Approved, Investigational Phase 4
Pantoprazole Approved Phase 4 102625-70-7 4679
Glimepiride Approved Phase 4 93479-97-1 3476
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Simvastatin Approved Phase 4 79902-63-9 54454
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
Glucagon Approved Phase 4 16941-32-5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Pravastatin Approved Phase 4 81093-37-0 54687
Molsidomine Approved, Investigational Phase 4 25717-80-0
Dobutamine Approved Phase 4 34368-04-2 36811
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Fenofibrate Approved Phase 4 49562-28-9 3339
Liraglutide Approved Phase 4 204656-20-2 44147092
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Insulin glargine Approved Phase 4 160337-95-1
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
Cefpirome Approved Phase 4 84957-29-9 5479539
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Empagliflozin Approved Phase 4 864070-44-0
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
Cangrelor Approved Phase 4 163706-06-7 9854012
Fondaparinux Approved, Investigational Phase 4 104993-28-4
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233

Interventional clinical trials:

(show top 50) (show all 1831)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Atorvastatin to Treat Variant Angina Unknown status NCT00620204 Phase 4 atorvastatin
2 A Prospective, Single-center, Randomized Study to Evaluate the Effect of Sarpogrelate, a Selective Serotonin Receptor Antagonist, and High Dose Statin on the Reduction of Coronary Spasm in the Patients With Variant Angina Unknown status NCT01674686 Phase 4 Sarpogrelate;Atorvastatin
3 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
4 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
5 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
6 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
7 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
8 Randomized Study on SCS for the Treatment of Refractory Angina Pectoris Unknown status NCT00121654 Phase 4
9 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
10 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
11 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
12 Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Unknown status NCT02284048 Phase 4 ticagrelor
13 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
14 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
15 Effect of Vitamin C Infusion on Coronary Reperfusion Indexes Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
16 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention Unknown status NCT03044964 Phase 4 Ranolazine;Placebo
17 Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02280850 Phase 4 Guanxin Shutong Capsule;Placebo Capsule;nitroglycerine
18 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
19 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
20 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
21 Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus. Unknown status NCT01735825 Phase 4
22 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
23 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
24 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
25 the Effect of Nifedipine Controlled Release Tablets in Hypertensive Patients on Chronic Maintenance Hemodialysis and the Influence of Hemodialysis on the Plasma Concentration of Nifedipine Unknown status NCT01021501 Phase 4 nifedipine controlled release tablets
26 Evaluation of Radial Strain Versus Fractional Shortening and Fractional Area Change for Assessment of Left Ventricular Function in Transesophageal Echocardiography Unknown status NCT01080495 Phase 4
27 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
28 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
29 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
30 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
31 Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) Unknown status NCT03486561 Phase 4 Ranolazine
32 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
33 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
34 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
35 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
36 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
37 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
38 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
39 The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
40 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
41 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
42 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
43 TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
44 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
45 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
46 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
47 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
48 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
49 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
50 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading

Search NIH Clinical Center for Angina Pectoris

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Amlodipine Besylate
Diltiazem Hydrochloride
Diltiazem maleate
Nicardipine hydrochloride
Verapamil hydrochloride

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Angina Pectoris cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: angina pectoris, variant

Genetic Tests for Angina Pectoris

Anatomical Context for Angina Pectoris

MalaCards organs/tissues related to Angina Pectoris:

Heart, Testes, Endothelial, Spinal Cord, Lung, Bone, Kidney

Publications for Angina Pectoris

Articles related to Angina Pectoris:

(show top 50) (show all 19268)
# Title Authors PMID Year
Prospective randomized controlled trial study of Luofengning granule in the treatment of unstable angina. 42
32443306 2020
Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. 42
32227753 2020
Microvascular Angina Diagnosed by Absolute PET Myocardial Blood Flow Quantification. 42
31993834 2020
Endothelial nitric oxide synthase T-786C mutation, a reversible etiology of Prinzmetal's angina pectoris. 54 61
20211321 2010
Neural responses during acute mental stress are associated with angina pectoris. 61
32345456 2020
Systemic Cardiac Troponin T Associated With Incident Atrial Fibrillation Among Patients With Suspected Stable Angina Pectoris. 61
32423695 2020
Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies. 61
32382156 2020
Early diastolic strain rate by two-dimensional speckle tracking echocardiography is a predictor of coronary artery disease and cardiovascular events in stable angina pectoris. 61
32405734 2020
Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. 61
31929322 2020
Exercise Electrocardiography and Computed Tomography Coronary Angiography for Patients With Suspected Stable Angina Pectoris: A Post Hoc Analysis of the Randomized SCOT-HEART Trial. 61
32492104 2020
Relationship between elevated plasma ceramides and plaque rupture in patients with ST-segment elevation myocardial infarction. 61
32387714 2020
Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention. 61
32533314 2020
Cumulative Exposure to Long Working Hours and Occurrence of Ischemic Heart Disease: Evidence From the CONSTANCES Cohort at Inception. 61
32476603 2020
Evaluation of the Manchester triage system for patients with acute coronary syndrome. 61
32240362 2020
Prognostic Significance of the Residual SYNTAX Score and Ischemic Reduction Detected with Nuclear Cardiology for Prediction of Major Cardiac Events after Revascularization. 61
32161215 2020
Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR. 61
31693092 2020
Utility of angiography-physiology coregistration maps during percutaneous coronary intervention in clinical practice. 61
32507942 2020
Increased Activity in Patients with Cardiovascular Risk Factors Increases Heart Rate Variability. 61
31328670 2020
Off-pump coronary artery bypass grafting via left anterior thoracotomy from the 4th costal space in a patient with total laryngectomy and a permanent tracheostoma. 61
31111321 2020
Natural cardiac death after stent implantation with iatrogenic injury of a coronary artery. 61
31713779 2020
A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden. 61
32525878 2020
Datasets describing the introduction of the high-sensitive troponin in the emergency department. 61
32322624 2020
Network pharmacology-based therapeutic mechanism of Kuanxiong aerosol for angina pectoris. 61
32526337 2020
Survival of Patients With Angina Pectoris Undergoing Percutaneous Coronary Intervention With Intracoronary Pressure Wire Guidance. 61
32498806 2020
Dietary choline is related to increased risk of acute myocardial infarction in patients with stable angina pectoris. 61
31707100 2020
Treatment of stable ischaemic heart disease: the old and the new. 61
32523440 2020
(Epicardial and microvascular) angina or atypical chest pain: differential diagnoses with cardiovascular magnetic resonance. 61
32523454 2020
Optical coherence tomography-verified longer balloon inflation time may provide better stent apposition and optimal index parameters. 61
30191264 2020
Physical Activity and the Risk for Sudden Cardiac Death in Patients With Coronary Artery Disease. 61
32433894 2020
Healed Plaques in Patients With Stable Angina Pectoris. 61
32295419 2020
[The organizational clinical system of development of medical care based on electronic personified data of medical services under angina pectoris and myocardium infarction]. 61
32526129 2020
[Chemical and pharmacological progress on a Tibetan folk medicine formula Bawei Chenxiang Powder]. 61
32495555 2020
Coronary artery bypass graft combined with liver transplantation in patients with advanced alcoholic liver cirrhosis: A case report. 61
32266015 2020
Sex and Age Differences in Patients With Unstable Angina Pectoris: A Single-Center Retrospective Study. 61
32563567 2020
Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. 61
32495911 2020
Lipid parameters and vitamin A modify cardiovascular risk prediction by plasma neopterin. 61
32398245 2020
mRNA expression disturbance of complement system related genes in acute arterial thrombotic and paroxysmal atrial fibrillation patients. 61
32389013 2020
Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. 61
32446298 2020
Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome. 61
32474302 2020
The Case for Primary Prevention of Atherosclerotic Events from Study of a Single Patient. 61
32005440 2020
The association between heart diseases and suicide: a nationwide cohort study. 61
31960499 2020
Effectiveness of Trimetazidine in Patients with Stable Angina Pectoris of Various Durations: Results from ODA. 61
32430799 2020
Improvement in quality of life and angina pectoris: 1-year follow-up of patients with refractory angina pectoris and spinal cord stimulation. 61
32430654 2020
Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach. 61
32447519 2020
Transsulfuration metabolites and the association with incident atrial fibrillation - An observational cohort study among Norwegian patients with stable angina pectoris. 61
32389762 2020
The impact of the coronary sinus reducer upon left ventricular function in patients with refractory angina pectoris. 61
31373415 2020
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry). 61
32540170 2020
[Hypertrophic cardiomyopathy]. 61
32185419 2020
The effect of Shexiang Tongxin Dropping Pills on coronary microvascular dysfunction (CMVD) among those with a mental disorder and non-obstructive coronary artery disease based on stress cardiac magnetic resonance images: A study protocol. 61
32481277 2020
CHA2DS2-Vasc score and saphenous vein graft disease in patients with coronary artery bypass graft surgery. 61
31658138 2020

Variations for Angina Pectoris

Expression for Angina Pectoris

LifeMap Discovery
Genes differentially expressed in tissues of Angina Pectoris patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 4.04 0.001
Search GEO for disease gene expression data for Angina Pectoris.

Pathways for Angina Pectoris

GO Terms for Angina Pectoris

Cellular components related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 PLAT NPPB LPA KNG1 INS IL6
2 endoplasmic reticulum lumen GO:0005788 9.56 KNG1 INS IL6 APOA1
3 collagen-containing extracellular matrix GO:0062023 9.55 PLAT KNG1 F3 APOA1 ADIPOQ
4 extracellular space GO:0005615 9.36 PLAT NPPB KNG1 INS IL6 F3

Biological processes related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 NOS3 INS IL6 F3 CRP
2 cellular protein metabolic process GO:0044267 9.78 KNG1 INS IL6 APOA1
3 cellular response to drug GO:0035690 9.67 HTR1B EDN1 ADIPOQ
4 response to hypoxia GO:0001666 9.67 PLAT MB EDN1 ADIPOQ
5 heart contraction GO:0060047 9.61 TNNI3 ACE
6 positive regulation of renal sodium excretion GO:0035815 9.6 NPPB EDN1
7 positive regulation of urine volume GO:0035810 9.59 NPPB EDN1
8 negative regulation of blood coagulation GO:0030195 9.58 KNG1 EDN1
9 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.58 CRP ADIPOQ
10 negative regulation of hormone secretion GO:0046888 9.57 EDN1 ADIPOQ
11 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.56 APOA1 ADIPOQ
12 negative regulation of blood vessel diameter GO:0097756 9.55 INS CRP
13 negative regulation of lipid storage GO:0010888 9.54 IL6 CRP
14 body fluid secretion GO:0007589 9.52 NPPB EDN1
15 acute-phase response GO:0006953 9.5 INS IL6 CRP
16 negative regulation of hydrolase activity GO:0051346 9.46 NOS3 APOA1
17 neutrophil mediated immunity GO:0002446 9.43 IL6 ACE
18 brown fat cell differentiation GO:0050873 9.43 MB ADRB1 ADIPOQ
19 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.4 NOS3 EDN1
20 negative regulation of proteolysis GO:0045861 9.33 PLAT KNG1 INS
21 regulation of blood vessel diameter GO:0097746 9.13 NPPB NOS3 ACE
22 regulation of blood pressure GO:0008217 8.92 NPPB NOS3 EDN1 ACE

Molecular functions related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.26 NPPB INS EDN1 ADIPOQ
2 signaling receptor binding GO:0005102 9.1 PLAT NPPB KNG1 EDN1 APOA1 ADIPOQ

Sources for Angina Pectoris

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....